- Bioxytran (OTCQB: BIXT) has published a groundbreaking book that supports its clinical development program for stroke and Alzheimer's treatments.
- The company's universal oxygen carrier (UOC) aims to replace hyperbaric oxygen treatment by delivering therapeutic oxygen at the cellular level.
- Research using the Mongolian gerbil brain model offers critical insights, validated by the FDA-approved MDX Viewer for measuring tissue oxygenation.
Bioxytran Inc. (OTCQB: BIXT), a clinical-stage biotechnology company, is making strides in the treatment of ischemic stroke and Alzheimer’s disease. The recent publication by Prof. Avraham Mayevsky, focused on Mongolian Gerbil brain research, serves as a foundational scientific resource validating Bioxytran's universal oxygen carrier (UOC) technology. This novel approach is designed to replace traditional hyperbaric oxygen treatment by delivering therapeutic oxygen at the cellular level, while avoiding the harmful reactive oxygen species associated with hyperbaric treatments.
The research utilizes the Mongolian gerbil, recognized for its unique brain vasculature that lacks compensatory mechanisms during stroke, making it ideal for studying stroke pathophysiology. This model, alongside the MDX Viewer approved by the FDA for measuring tissue oxygenation, provides significant predictive value in clinical trials for stroke and neurodegenerative diseases such as Alzheimer's.
Bioxytran's UOC technology, combined with real-time metabolic insights from the MDX Viewer, positions the company at the forefront of advancements in brain health treatments. The insights from this research are expected to contribute substantially to the understanding and treatment of stroke and neurodegenerative diseases, as highlighted by Prof. Mayevsky's extensive work.
While Bioxytran continues in the clinical development stage, with its UOC and related technologies not yet commercially available, the company's efforts signal a potentially transformative approach to critical brain-related medical conditions.
